Imaging, Biomarkers, and Cancer

The landscape is constantly evolving for imaging technology and biomarkers, and how they impact cancer detection and treatment. Frost & Sullivan has provided AABME with market intelligence on key innovations for imaging and biomarker technology for oncology.

August 12, 2017

Imaging forms an essential part of cancer clinical protocols and is able to furnish morphological, structural, metabolic and functional information. It is used to screen, diagnose and stage cancer, guide cancer treatments, determine the effectiveness of cancer therapy and monitor cancer recurrence. Integration of oncology medical imaging with other clinical tools, such as in vitro tissue analysis, biomarker tests, and cancer screening, improves decision making. Early detection through screening based on imaging is the major contributor to a reduction in the number of deaths caused by certain types of cancers. The landscape is constantly evolving for imaging technology and biomarkers, and how they impact cancer detection and treatment. Frost & Sullivan has provided the Alliance of Advanced Biomedical Engineering with market intelligence on key innovations for imaging and biomarker technology for oncology.

Want the full article?

Sign up for AABME's Technology & Industry Updates for FREE by Wednesday, August 23 to be included on the distribution list.